Citation: | WU Li'na, GAO Yi, LI Wosong, LIU Yong, QIN Xiaosong. Application Value of Serum Kreb Von Den Lungen-6 in the Adjuvant Treatment of Lung Injury after Non-small Cell Lung Cancer Surgery[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(4): 496-502. DOI: 10.12290/xhyxzz.2021-0308 |
[1] |
Zeng H, Chen W, Zheng R, et al. Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries[J]. Lancet Glob Health, 2018, 6: e555-e567. DOI: 10.1016/S2214-109X(18)30127-X
|
[2] |
孙建国, 李梦侠, 杨镇洲. PD-L1高表达晚期非小细胞肺癌一线免疫治疗策略的探讨[J]. 第三军医大学学报, 2020, 42: 314-319. https://www.cnki.com.cn/Article/CJFDTOTAL-DSDX202003017.htm
Sun JG, Li MX, Yang ZZ. First line immunotherapy for advanced non-small cell lung cancer with high expression of PD-L1[J]. Di-san Junyi Daxue Xuebao, 2020, 42: 314-319. https://www.cnki.com.cn/Article/CJFDTOTAL-DSDX202003017.htm
|
[3] |
Abe M, Tsushima K, Ikari J, et al. Evaluation of the clinical characteristics of everolimus- induced lung injury and determination of associated risk factors[J]. Respir Med, 2018, 134: 6-11. DOI: 10.1016/j.rmed.2017.11.009
|
[4] |
王绿化, 傅小龙, 陈明, 等. 放射性肺损伤的诊断与治疗[J]. 中华放射肿瘤学杂志, 2015, 24: 4-9. DOI: 10.3760/cma.j.issn.1004-4221.2015.01.003
Wang LH, Fu XL, Chen M, et al. Diagnosis and treatment of radiation-induced lung injury[J]. Zhonghua Fangshe Zhongliuxue Zazhi, 2015, 24: 4-9. DOI: 10.3760/cma.j.issn.1004-4221.2015.01.003
|
[5] |
Kohno N, Akiyama M, Kyoizumi S, et al. Detection of solubletumor-associated antigen in sera and effusions using novelmonoclonal antibodies, KL-3 and KL-6, against lungadeno-carcinoma[J]. Jpn J Clin Oncol, 1988, 18: 203-216.
|
[6] |
Ballester B, Milara J, Cortijo J. Mucinsas a New Frontier inPulmonaryFibrosis[J]. J Clin Med, 2019, 8: 1447. DOI: 10.3390/jcm8091447
|
[7] |
Ishikawa N, Hattori N, Yokoyama A, et al. Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases[J]. Respir Investig, 2012, 50: 3-13. DOI: 10.1016/j.resinv.2012.02.001
|
[8] |
Kubo K, Azuma A, Kanazawa M, et al. Consensus state-ment for the diagnosis andtreatment of drug-induced lung injuries[J]. Respir Investig, 2013, 51: 260-277. DOI: 10.1016/j.resinv.2013.09.001
|
[9] |
中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)原发性肺癌诊疗指南2019[M]. 北京: 人民卫生出版社, 2019: 1-18.
|
[10] |
周惠琼, 张奉春. 涎液化糖链抗原-6在间质性肺疾病诊疗中的价值[J]. 协和医学杂志, 2018, 9: 207-212. DOI: 10.3969/j.issn.1674-9081.2018.03.004
Zhou HQ, Zhang FC. The value of Kreb von den lungen-6 in the diagnosis and treatment of interstitial lung disease[J]. Xiehe Yixue Zazhi, 2018, 9: 207-212. DOI: 10.3969/j.issn.1674-9081.2018.03.004
|
[11] |
Peng DH, Luo Y, Huang LJ, et al. Correlation of Krebs von den Lungen-6 and fibronectin with pulmonary fibrosis in coronavirus disease 2019[J]. Clin Chim Acta, 2021, 517: 48-53. DOI: 10.1016/j.cca.2021.02.012
|
[12] |
Bergantini L, Bargagli E, d'Alessandro M, et al. Prognosticbioindicatorsin severe COVID-19 patients[J]. Cytokine, 2021, 141: 155455. DOI: 10.1016/j.cyto.2021.155455
|
[13] |
Scotto R, Pinchera B, Perna F, et al. Serum KL-6 Could Represent a Reliable Indicator of Unfavourable Outcome in Patients with COVID-19 Pneumonia[J]. Int J Environ Res Public Health, 2021, 18: 2078. DOI: 10.3390/ijerph18042078
|
[14] |
Iwata H, Shibamoto Y, Baba F, et al. Correlation between the serum KL-6 level and the grade of radiation pneumonitis after stereotactic body radiotherapy for stage I lung cancer or small lung metastasis[J]. Radiother Oncol, 2011, 101: 267-270. DOI: 10.1016/j.radonc.2011.05.031
|
[15] |
Matsuno Y, Satoh H, Ishikawa H, et al. Simultaneous measurements of KL-6 and SP-D in patients undergoing thoracic radiotherapy[J]. Med Oncol, 2006, 23: 75-81. DOI: 10.1385/MO:23:1:75
|
[16] |
Tanaka S, Hattori N, Ishikawa N, et al. Krebs von den Lungen-6 (KL-6) is a prognostic biomarker in patients with surgically resected nonsmall cell lung cancer[J]. Int J Cancer, 2012, 130: 377-387. DOI: 10.1002/ijc.26007
|
[17] |
Ishikawa N, Hattori N, Yokoyama A, et al. Usefulness of monitoring the circulating Krebs von den Lungen-6 levels to predict the clinical outcome of patients with advancednon-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors[J]. Int J Cancer, 2008, 122: 2612-2620. DOI: 10.1002/ijc.23411
|
[18] |
Ogawa Y, Ishikawa T, Ikeda K, et al. Evaluation of serum KL-6, a mucin-like glycoprotein, as a tumor marker for breast cancer[J]. Clin Cancer Res, 2000, 6: 4069-4072. http://www.ncbi.nlm.nih.gov/pubmed/11051258
|
[19] |
Inata J, Hattori N, Yokoyama A, et al. Circulating KL-6/MUC1 mucin carrying sialyl Lewisa oligosaccharide is an independent prognostic factor in patients with lung adenocarcinoma[J]. Int J Cancer, 2007, 120: 2643-2649. DOI: 10.1002/ijc.22613
|
[20] |
Kawase S, Hattori N, Ishikawa N, et al. Change in serum KL-6 level from baseline is useful for predicting life-threatening EGFR-TKIs induced interstitial lung disease[J]. Respir Res, 2011, 12: 97. DOI: 10.1186/1465-9921-12-97
|
[1] | WANG Shuo, DENG Yuntian, PENG Huan, ZHANG Xiangfeng. Progress in the Treatment of Non-small Cell Lung Cancer with Immune Checkpoint Inhibitors[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(2): 409-415. DOI: 10.12290/xhyxzz.2022-0151 |
[2] | DAI Liyuan, SHI Yuankai, HAN Xiaohong. Advances in Dynamic Monitoring of Immune Checkpoint Inhibitors as the Prognostic Markers for Advanced Non-small Cell Lung Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(2): 287-295. DOI: 10.12290/xhyxzz.2021-0608 |
[3] | LI Guo-yu, HE Ming. Research Progress of Targeted Therapy at Rare Targets for Non-small Cell Lung Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(2): 268-274. DOI: 10.3969/j.issn.1674-9081.2020.00.019 |
[4] | Lei LIU, Jia-qi ZHANG, Gui-ge WANG, Cheng HUANG, Li LI, Nai-xin LIANG, Shan-qing LI. Fibroblast Growth Factor Receptor 1 in Non-small Cell Lung Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(6): 666-672. DOI: 10.3969/j.issn.1674-9081.2019.06.020 |
[5] | Jia-qi ZHANG, Lei LIU, Gui-ge WANG, Wen-liang BAI, Shan-qing LI. Clinical Pathological Features and Prognosis of Non-small Cell Lung Cancer with Skip N2 Lymph Node Metastasis[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(3): 272-277. DOI: 10.3969/j.issn.1674-9081.2019.03.015 |
[6] | Hui-qiong ZHOU, Feng-chun ZHANG. The Value of Krebs von den Lungen-6 in the Clinical Management of Interstitial Lung Diseases[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(3): 207-212. DOI: 10.3969/j.issn.1674-9081.2018.03.004 |
[7] | Xiao-na JIN, Nai-xin LIANG, Meng-zhao WANG, Bing JIA, Xi-min SHI, Shan-qing LI, Fang LI, Fan WANG, Zhao-hui ZHU. Integrin Receptor Imaging 99mTc-3PRGD2 SPECT/CT in Diagnosis and Lymph Node Staging of Non-Small Cell Lung Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2016, 7(5): 327-333. DOI: 10.3969/j.issn.1674-9081.2016.05.002 |
[8] | Nai-xin LIANG, Ya-xin LIU, Lei LIU, Shan-qing LI. Co-mutation of PIK3CA and Other Oncogenes in Patients with Non-small Cell Lung Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2015, 6(3): 186-190. DOI: 10.3969/j.issn.1674-9081.2015.03.005 |
[9] | Xiao-hong NING, Yu-zhou WANG, Zhao SUN, Ji LI, Yan-ping ZHOU, Chun-mei BAI. Role of ERCC1 Expression in Predicting the Outcome of Platinum-based Chemotherapy in Patients with End-stage Non-small-cell Lung Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2010, 1(2): 155-159. |
[10] | Jing ZHANG, Zhi-yong LIANG, Jie GAO, Tong-hua LIU. Relationship between the Mutations of Epidermal Growth Factor Receptor Gene and k-ras Gene and the Clinicopathological Features of Non-small Cell Lung Cancers[J]. Medical Journal of Peking Union Medical College Hospital, 2010, 1(1): 53-59. |